Together, these opposing transcriptional patterns are consistent with the emerging notion that elevated TMBIM6 expression contributes to an immunosuppressive tumor microenvironment in PRAD, promoting tumor cell fitness while dampening anti-tumor immune pressure. Here, TMBIM6 is linked to prostate adenocarcinoma.